Audit in process? Call the number on your audit letter to get options.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 22, 2018 - The FDA announced the approval of Dompé's Oxervate (cenegermin-bkbj) for the treatment of neurotrophic keratitis.
Download PDF
Return to publications
